

MATERIALS LICENSE

Amendment No. 12

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Corrected Copy

<p>Licensee</p> <p>1. American Diagnostic Medicine</p> <p>2. 960 Industrial Drive Suite 7 Elmhurst, IL 60126</p>	<p>In accordance with letter dated July 22, 2008,</p> <p>3. License number 12-32597-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date October 31, 2015</p> <hr/> <p>5. Docket No. 030-37037 Reference No.</p>
--------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p>
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------

9. Authorized use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
 - B. Any imaging and localization study permitted by 10 CFR 35.200.

CONDITIONS

- 10. Licensed material may be stored at 1 Tidland Road, Oak Ridge, New Jersey, and may be used at **207 N. Townline Road, LaGrange, Indiana**, and at temporary job sites of the licensee anywhere in the United States where the U.S. Nuclear Regulatory Commission maintains jurisdiction for regulating the use of licensed material, including areas of exclusive Federal jurisdiction within Agreement States.
- 11. The Radiation Safety Officer for this license is Ray A. Carlson, M.S.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
12-32597-01

Docket or Reference Number
030-37037

Amendment No. 12
Corrected Copy

12. Licensed material is only authorized for use by, or under the supervision of:

- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

<u>Authorized Users</u>	<u>Material and Use</u>
Antoine M. Adem, M.D.	10 CFR 35.100 and 35.200.
Mark Sabbota, M.D.	10 CFR 35.100 and 35.200.
Vemblaserry Jayablan, M.D.	10 CFR 35.100 and 35.200.
Apparao Mukkamala, M.D.	10 CFR 35.100 and 35.200.
Paul Lauber, M.D.	10 CFR 35.100 and 35.200.
M. Rao Tummala, M.D.	10 CFR 35.100 and 35.200.
Michael Lala, M.D.	10 CFR 35.100 and 35.200.
David Salvati, M.D.	10 CFR 35.100 and 35.200.
David Shipon, M.D.	10 CFR 35.100 and 35.200.
Brian David Fedgchin, M.D.	10 CFR 35.100 and 35.200.
David M. Reiner, M.D.	10 CFR 35.100 and 35.200.
Andrew M. Keenan, M.D.	10 CFR 35.100 and 35.200.
Brett A. Hagedorn, M.D.	10 CFR 35.100 and 35.200.
John Rock, M.D.	10 CFR 35.100 and 35.200.
Rik Stephens, M.D.	10 CFR 35.100 and 35.200.
James C. Wehrenberg, M.D.	10 CFR 35.100 and 35.200.
James A. Arata, M.D.	10 CFR 35.100 and 35.200.
David B Janizek, M.D.	10 CFR 35.100 and 35.200.
Christine A. Tremper, M.D.	10 CFR 35.100 and 35.200.


**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
12-32597-01Docket or Reference Number
030-37037**Amendment No. 12**
Corrected CopyAuthorized UsersMaterial and Use

Randall J. Phillips, M.D.	10 CFR 35.100 and 35.200.
John Pasalich, M.D.	10 CFR 35.100 and 35.200.
Stephen R. Phillip, M.D.	10 CFR 35.100 and 35.200.
Marc Thomas, M.D.	10 CFR 35.100 and 35.200.
Diane D. Daly, M.D.	10 CFR 35.100 and 35.200.
John L. Bormann, M.D.	10 CFR 35.100 and 35.200.
Michael E. Parker, M.D.	10 CFR 35.100 and 35.200.
Pamela L. Strange, M.D.	10 CFR 35.100 and 35.200.
Michael W. Tanksley, M.D.	10 CFR 35.100 and 35.200.
Joseph R. Decamp, M.D.	10 CFR 35.100 and 35.200.
John R. Kim, M.D.	10 CFR 35.100 and 35.200.
Frederick N. Vandeman, M.D.	10 CFR 35.100 and 35.200.
Andre Byard Stovall, M.D.	10 CFR 35.100 and 35.200.
Christopher M. Kowalski, M.D.	10 CFR 35.100 and 35.200.
Dakshesh S. Patel, M.D.	10 CFR 35.100 and 35.200.
Richard W. Sibley, M.D.	10 CFR 35.100 and 35.200.
Eric V. Heatwole, M.D.	10 CFR 35.100 and 35.200.
Shilpa Kashyap, M.D.	10 CFR 35.100 and 35.200.
Brian Kim, M.D.	10 CFR 35.100 and 35.200.
Shawn Johnson, M.D.	10 CFR 35.100 and 35.200.
Sandeep S. Ahluwalia, M.D.	10 CFR 35.100 and 35.200.
John C. Lacunza, M.D.	10 CFR 35.100 and 35.200.
Linda G. Hippenhammer, M.D.	10 CFR 35.100 and 35.200.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
12-32597-01Docket or Reference Number
030-37037**Amendment No. 12**
Corrected Copy

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated September 28, 2005 (excluding facility diagram); and
- B. Letters dated October 6, 2005, October 24, 2005, October 26, 2005, November 9, 2005, June 29, 2006, October 3, 2006, December 16, 2007, March 6, 2008, **June 23, 2008, July 22, 2008**; and
- C. Facsimiles dated July 10, 2006, July 27, 2007, January 10, 2008, and March 10, 2008.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date SEP 12 2008By 
James R. Mullauer, M.H.S.
Materials Licensing Branch
Region III